GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.

Direct download: GRACEcast-118_Lung-Video_ASCO_2012_Q_and_A_10.m4v
Category:Lung-Cancer-Video -- posted at: 12:32pm PDT

Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.

Direct download: GRACEcast-118_Lung-Audio_ASCO_2012_Q_and_A_10.mp3
Category:Lung-Cancer-Audio -- posted at: 12:30pm PDT

Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.

Direct download: GRACEcast-117_Lung-Video_ASCO_2012_Neal_9.m4v
Category:Lung-Cancer-Video -- posted at: 8:00am PDT

Dr. Joel Neal presents interesting early data demonstrating that squamous NSCLC often features identifiable molecular markers that can potentially be targeted by novel therapies.

Direct download: GRACEcast-117_Lung-Audio_ASCO_2012_Neal_9.mp3
Category:Lung-Cancer-Audio -- posted at: 8:00am PDT

Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer. 

Direct download: GRACEcast-116_Lung-Video_ASCO_2012_Neal_8.m4v
Category:Lung-Cancer-Video -- posted at: 4:11pm PDT

Dr. Joel Neal summarizes preliminary results of the SELECT trial of adjuvant Tarceva (erlotinib) for patients with resected EGFR mutation-positive early stage non-small cell lung cancer. 

Direct download: GRACEcast-116_Lung-Audio_ASCO_2012_Neal_8.mp3
Category:Lung-Cancer-Audio -- posted at: 4:11pm PDT

Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.

Direct download: GRACEcast-115_Lung-Video_ASCO_2012_Neal_7.m4v
Category:Lung-Cancer-Video -- posted at: 12:29am PDT

Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.

Direct download: GRACEcast-115_Lung-Audio_ASCO_2012_Neal_7.mp3
Category:Lung-Cancer-Audio -- posted at: 12:29am PDT

Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).

Direct download: GRACEcast-114_Lung-Video_ASCO_2012_Neal_6.m4v
Category:Lung-Cancer-Video -- posted at: 8:57pm PDT

Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).

Direct download: GRACEcast-114_Lung-Audio_ASCO_2012_Neal_6.mp3
Category:Lung-Cancer-Audio -- posted at: 8:56pm PDT